Moreover, although IL-6 in complexes in the circulation has been largely ignored by clinical investigators, this issue becomes critical in cancer patients administered immunotherapy with “neutralizing” anti-IL-6 mAb (as in multiple myeloma and Castleman’s disease) and COVID-19. Here, IL6 is linked to Castleman disease.